Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy

References

• EvansWERellingMVPharmacogenomics: translating functional genomics into rational therapeuticsScience199928648749110521338
   PubMed Web of Science ®Google Scholar
• FruehFWAmurSMummaneniPPharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug usePharmacotherapy20082899299818657016
   PubMed Web of Science ®Google Scholar
• BradfordLDCYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendantsPharmacogenomics2002322924311972444
   PubMed Web of Science ®Google Scholar
• ZhouSFLiuJPChowbayBPolymorphism of human cytochrome P450 enzymes and its clinical impactDrug Metab Rev2009418929519514967
   PubMed Web of Science ®Google Scholar
• HigashiMKVeenstraDLKondoLMAssociation between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapyJAMA20022871690169811926893
   PubMed Web of Science ®Google Scholar
• GuillemetteCPharmacogenomics of human UDP-glucuronosyltransferase enzymesPharmacogenomics J20033313615812815363
   PubMed Web of Science ®Google Scholar
• NagarSRemmelRPUridine diphosphoglucuronosyltransferase pharmacogenetics and cancerOncogene2006251659167216550166
   PubMed Web of Science ®Google Scholar
• GlattHMeinlWPharmacogenetics of soluble sulfotransferases (SULTs)Naunyn Schmiedebergs Arch Pharmacol2004369556814600802
   PubMed Web of Science ®Google Scholar
• NowellSFalanyCNPharmacogenetics of human cytosolic sulfotransferasesOncogene2006251673167816550167
   PubMed Web of Science ®Google Scholar
• LoHWAli-OsmanFGenetic polymorphism and function of glutathione S-transferases in tumor drug resistanceCurr Opin Pharmacol2007736737417681492
   PubMed Web of Science ®Google Scholar
• McIlwainCCTownsendDMTewKDGlutathione S-transferase polymorphisms: cancer incidence and therapyOncogene2006251639164816550164
   PubMed Web of Science ®Google Scholar
• BlumMGrantDMMcBrideWHuman arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expressionDNA Cell Biol199091932032340091
   PubMed Web of Science ®Google Scholar
• SimELackNWangCJArylamine N-acetyltransferases: structural and functional implications of polymorphismsToxicology200825417018318852012
   PubMed Web of Science ®Google Scholar
• HuangYSChernHDSuWJPolymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitisHepatology20023588388911915035
   PubMed Web of Science ®Google Scholar
• HeinDWMolecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesisMutat Res2002506–5076577
   PubMed Web of Science ®Google Scholar
• CartwrightRAGlashanRWRogersHJRole of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancerLancet198228428456126711
   PubMed Web of Science ®Google Scholar
• Garcia-ClosasMMalatsNSilvermanDNAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analysesLancet200536664965916112301
   PubMed Web of Science ®Google Scholar
• ZhouSClinical pharmacogenomics of thiopurine S-methyltransferaseCurr Clin Pharmacol2006111912818666383
   PubMedGoogle Scholar
• RellingMVGardnerEESandbornWJClinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingClin Pharmacol Ther20118938739121270794
   PubMed Web of Science ®Google Scholar
• KerbRImplications of genetic polymorphisms in drug transporters for pharmacotherapyCancer Lett200623443316504381
   PubMed Web of Science ®Google Scholar
• GottesmanMMFojoTBatesSEMultidrug resistance in cancer: role of ATP-dependent transportersNat Rev Cancer20022485811902585
   PubMed Web of Science ®Google Scholar
• WacherVJWuCYBenetLZOverlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapyMol Carcinog1995131291347619215
   PubMed Web of Science ®Google Scholar
• HoffmeyerSBurkOvon RichterOFunctional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProc Natl Acad Sci U S A2000973473347810716719
   PubMed Web of Science ®Google Scholar
• Kimchi-SarfatyCOhJMKimIWA “silent” polymorphism in the MDR1 gene changes substrate specificityScience200731552552817185560
   PubMed Web of Science ®Google Scholar
• IeiriITakaneHOtsuboKThe MDR1 (ABCB1) gene polymorphism and its clinical implicationsClin Pharmacokinet20044355357615217301
   PubMed Web of Science ®Google Scholar
• Pauli-MagnusCKroetzDLFunctional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)Pharm Res20042190491315212152
   PubMed Web of Science ®Google Scholar
• MarzoliniCPausEBuclinTPolymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClin Pharmacol Ther200475133314749689
   PubMed Web of Science ®Google Scholar
• SakaedaTMDR1 genotype-related pharmacokinetics: fact or fiction?Drug Metab Pharmacokinet20052039141416415525
   PubMedGoogle Scholar
• HinoshitaEUchiumiTTaguchiKIncreased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomasClin Cancer Res200062401240710873092
   PubMed Web of Science ®Google Scholar
• RothnieACallaghanRDeeleyRGRole of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1)J Biol Chem2006281139061391416565074
   PubMed Web of Science ®Google Scholar
• GradhandUKimRBPharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2)Drug Metab Rev20084031735418464048
   PubMed Web of Science ®Google Scholar
• WojnowskiLKulleBSchirmerMNAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicityCirculation20051123754376216330681
   PubMed Web of Science ®Google Scholar
• Meyer zu SchwabedissenHEJedlitschkyGGratzMVariable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiationDrug Metab Dispos20053389690415821043
   PubMed Web of Science ®Google Scholar
• MeierYPauli-MagnusCZangerUMInterindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liverHepatology200644627416799996
   PubMed Web of Science ®Google Scholar
• IzzedineHHulotJSVillardEAssociation between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathyJ Infect Dis20061941481149117083032
   PubMed Web of Science ®Google Scholar
• VogelgesangSKunert-KeilCCascorbiIExpression of multi-drug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsyClin Neuropathol20042322323115581025
   PubMed Web of Science ®Google Scholar
• KrishnamurthyPSchuetzJDRole of ABCG2/BCRP in biology and medicineAnnu Rev Pharmacol Toxicol20064638141016402910
   PubMed Web of Science ®Google Scholar
• JonkerJWBuitelaarMWagenaarEThe breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyriaProc Natl Acad Sci U S A200299156491565412429862
   PubMed Web of Science ®Google Scholar
• JonkerJWSmitJWBrinkhuisRFRole of breast cancer resistance protein in the bioavailability and fetal penetration of topotecanJ Natl Cancer Inst2000921651165611036110
   PubMed Web of Science ®Google Scholar
• SparreboomALoosWJBurgerHEffect of ABCG2 genotype on the oral bioavailability of topotecanCancer Biol Ther2005465065815908806
   PubMed Web of Science ®Google Scholar
• BurgerHNooterKPharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinibCell Cycle200431502150515611623
   PubMed Web of Science ®Google Scholar
• KondoCOnukiRKusuharaHLack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2)Pharm Res20052261361815846469
   PubMed Web of Science ®Google Scholar
• MerinoGJonkerJWWagenaarEThe breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoinMol Pharmacol2005671758176415709111
   PubMed Web of Science ®Google Scholar
• HiranoMMaedaKMatsushimaSInvolvement of BCRP (ABCG2) in the biliary excretion of pitavastatinMol Pharmacol20056880080715955871
   PubMed Web of Science ®Google Scholar
• IidaASaitoSSekineACatalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8J Hum Genet20024728531012111378
   PubMed Web of Science ®Google Scholar
• ImaiYNakaneMKageKC421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistanceMol Cancer Ther2002161161612479221
   PubMed Web of Science ®Google Scholar
• ZamberCPLambaJKYasudaKNatural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestinePharmacogenetics200313192812544509
   PubMedGoogle Scholar
• IshikawaTTamuraASaitoHPharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular designNaturwissenschaften20059245146316160819
   PubMed Web of Science ®Google Scholar
• MitomoHKatoRItoAA functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transportBiochem J200337376777412741957
   PubMed Web of Science ®Google Scholar
• KobayashiDIeiriIHirotaTFunctional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placentaDrug Metab Dispos2005339410115475413
   PubMed Web of Science ®Google Scholar
• LepperERNooterKVerweijJMechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2Pharmacogenomics2005611513815882131
   PubMed Web of Science ®Google Scholar
• SparreboomAGelderblomHMarshSDiflomotecan pharmacokinetics in relation to ABCG2 421C>A genotypeClin Pharmacol Ther200476384415229462
   PubMed Web of Science ®Google Scholar
• LiJCusatisGBrahmerJAssociation of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsCancer Biol Ther2007643243817312388
   PubMed Web of Science ®Google Scholar
• CusatisGGregorcVLiJPharmacogenetics of ABCG2 and adverse reactions to gefitinibJ Natl Cancer Inst2006981739174217148776
   PubMed Web of Science ®Google Scholar
• NiemiMRole of OATP transporters in the disposition of drugsPharmacogenomics2007878780218240907
   PubMed Web of Science ®Google Scholar
• Meyer zu SchwabedissenHEKimRBHepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphismsMol Pharm200961644166119558188
   PubMed Web of Science ®Google Scholar
• KameyamaYYamashitaKKobayashiKFunctional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cellsPharmacogenet Genomics20051551352215970799
   PubMed Web of Science ®Google Scholar
• NozawaTMinamiHSugiuraSRole of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphismsDrug Metab Dispos20053343443915608127
   PubMed Web of Science ®Google Scholar
• TironaRGLeakeBFMerinoGPolymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-AmericansJ Biol Chem2001276356693567511477075
   PubMed Web of Science ®Google Scholar
• NiemiMPasanenMKNeuvonenPJSLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatinClin Pharmacol Ther20068035636617015053
   PubMed Web of Science ®Google Scholar
• NiemiMBackmanJTKajosaariLIPolymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokineticsClin Pharmacol Ther20057746847815961978
   PubMed Web of Science ®Google Scholar
• NishizatoYIeiriISuzukiHPolymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokineticsClin Pharmacol Ther20037355456512811365
   PubMed Web of Science ®Google Scholar
• XiangXJadaSRLiHHPharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patientsPharmacogenet Genomics20061668369116906022
   PubMed Web of Science ®Google Scholar
• HanJYLimHSShinESInfluence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancerLung Cancer200859697517766002
   PubMed Web of Science ®Google Scholar
• LinkEParishSArmitageJSLCO1B1 variants and statin-induced myopathym – a genomewide studyN Engl J Med200835978979918650507
   PubMed Web of Science ®Google Scholar
• FrankeRMScherkenbachLASparreboomAPharmacogenetics of the organic anion transporting polypeptide 1A2Pharmacogenomics20091033934419290786
   PubMed Web of Science ®Google Scholar
• LetschertKKepplerDKonigJMutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8)Pharmacogenetics20041444145215226676
   PubMedGoogle Scholar
• NozawaTNakajimaMTamaiIGenetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysisJ Pharmacol Exp Ther200230280481312130747
   PubMed Web of Science ®Google Scholar
• Hayer-ZillgenMBrussMBonischHExpression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3Br J Pharmacol200213682983612110607
   PubMed Web of Science ®Google Scholar
• ZhangSLovejoyKSShimaJEOrganic cation transporters are determinants of oxaliplatin cytotoxicityCancer Res2006668847885716951202
   PubMed Web of Science ®Google Scholar
• ChoiMKSongISOrganic cation transporters and their pharmacokinetic and pharmacodynamic consequencesDrug Metab Pharmacokinet20082324325318762711
   PubMed Web of Science ®Google Scholar
• PentikainenPJNeuvonenPJPenttilaAPharmacokinetics of metformin after intravenous and oral administration to manEur J Clin Pharmacol197916195202499320
   PubMed Web of Science ®Google Scholar
• SongISShinHJShimEJGenetic variants of the organic cation transporter 2 influence the disposition of metforminClin Pharmacol Ther20088455956218401339
   PubMed Web of Science ®Google Scholar
• WangZJYinOQTomlinsonBOCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidinePharmacogenet Genomics20081863764518551044
   PubMed Web of Science ®Google Scholar
• TzvetkovMVVormfeldeSVBalenDThe effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metforminClin Pharmacol Ther20098629930619536068
   PubMed Web of Science ®Google Scholar
• ShuYSheardownSABrownCEffect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJ Clin Invest20071171422143117476361
   PubMed Web of Science ®Google Scholar
• XuGBhatnagarVWenGAnalyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]Kidney Int2005681491149916164626
   PubMed Web of Science ®Google Scholar
• BhatnagarVXuGHamiltonBAAnalyses of 5’ regulatory region polymorphisms in human SLC22A6 (OAT1) and SLC22A8 (OAT3)J Hum Genet20065157558016648942
   PubMed Web of Science ®Google Scholar
• HeidelbergerCChaudhuriNKDannebergPFluorinated pyrimidines, a new class of tumour-inhibitory compoundsNature195717966366613418758
   PubMed Web of Science ®Google Scholar
• OmuraKClinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidinesInt J Clin Oncol2003813213812851836
   PubMedGoogle Scholar
• SoongRShahNSalto-TellezMPrognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapyAnn Oncol20081991591918245778
   PubMed Web of Science ®Google Scholar
• SalongaDDanenbergKDJohnsonMColorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylaseClin Cancer Res200061322132710778957
   PubMed Web of Science ®Google Scholar
• LuZZhangRDiasioRBDihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapyCancer Res199353543354388221682
   PubMed Web of Science ®Google Scholar
• MorelABoisdron-CelleMFeyLClinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil toleranceMol Cancer Ther200652895290417121937
   PubMed Web of Science ®Google Scholar
• VrekenPVan KuilenburgABMeinsmaRA point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiencyJ Inherit Metab Dis1996196456548892022
   PubMed Web of Science ®Google Scholar
• WeiXMcLeodHLMcMurroughJMolecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicityJ Clin Invest1996986106158698850
   PubMed Web of Science ®Google Scholar
• Van KuilenburgABVrekenPBeexLVHeterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicityEur J Cancer199733225822649470816
   PubMed Web of Science ®Google Scholar
• IchikawaWUetakeHShirotaYBoth gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancerBr J Cancer2003891486149214562021
   PubMed Web of Science ®Google Scholar
• IchikawaWTakahashiTSutoKOrotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimenClin Cancer Res2006123928393416818689
   PubMed Web of Science ®Google Scholar
• PullarkatSTStoehlmacherJGhaderiVThymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapyPharmacogenomics J20011657011913730
   PubMedGoogle Scholar
• KawakamiKOmuraKKanehiraEPolymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancersAnticancer Res1999193249325210652619
   PubMed Web of Science ®Google Scholar
• MandolaMVStoehlmacherJMuller-WeeksSA novel single nucleotide polymorphism within the 5’ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activityCancer Res2003632898290412782596
   PubMed Web of Science ®Google Scholar
• MandolaMVStoehlmacherJZhangWA 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levelsPharmacogenetics20041431932715115918
   PubMedGoogle Scholar
• LurjeGManegoldPCNingYPohlAZhangWLenzHJThymidylate synthase gene variations: predictive and prognostic markersMol Cancer Ther2009851000100719383851
   PubMed Web of Science ®Google Scholar
• SaltzLBCoxJVBlankeCIrinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupN Engl J Med200034390591411006366
   PubMed Web of Science ®Google Scholar
• SlatterJGSuPSamsJPBioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactionsDrug Metab Dispos199725115711649321519
   PubMed Web of Science ®Google Scholar
• RivoryLPRiouJFHaazMCIdentification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patientsCancer Res199656368936948706009
   PubMed Web of Science ®Google Scholar
• DoddsHMHaazMCRiouJFIdentification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38J Pharmacol Exp Ther19982865785839655905
   PubMed Web of Science ®Google Scholar
• LuoFRParanjpePVGuoAIntestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1Drug Metab Dispos20023076377012065434
   PubMed Web of Science ®Google Scholar
• SchellensJHMaliepaardMScheperRJTransport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implicationsAnn NY Acad Sci200092218819411193894
   PubMed Web of Science ®Google Scholar
• MathijssenRHvan AlphenRJVerweijJClinical pharmacokinetics and metabolism of irinotecan (CPT-11)Clin Cancer Res200172182219411489791
   PubMed Web of Science ®Google Scholar
• TukeyRHStrassburgCPMackenziePIPharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicityMol Pharmacol20026244645012181419
   PubMed Web of Science ®Google Scholar
• IyerLDasSJanischLUGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityPharmacogenomics J20022434711990381
   PubMedGoogle Scholar
• InnocentiFUndeviaSDIyerLGenetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanJ Clin Oncol2004221382138815007088
   PubMed Web of Science ®Google Scholar
• PremawardhenaAFisherCALiuYTThe global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implicationsBlood Cells Mol Dis2003319810112850492
   PubMed Web of Science ®Google Scholar
• HanJYLimHSShinESComprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatinJ Clin Oncol2006242237224416636344
   PubMed Web of Science ®Google Scholar
• KitagawaCAndoMAndoYGenetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicityPharmacogenet Genomics200515354115864124
   PubMedGoogle Scholar
• De JongFAde JongeMJVerweijJRole of pharmacogenetics in irinotecan therapyCancer Lett20062349010616343744
   PubMed Web of Science ®Google Scholar
• ZhouQSparreboomATanEHPharmacogenetic profiling across the irinotecan pathway in Asian patients with cancerBr J Clin Pharmacol20055941542415801936
   PubMed Web of Science ®Google Scholar
• MathijssenRHMarshSKarlssonMOIrinotecan pathway genotype analysis to predict pharmacokineticsClin Cancer Res200393246325312960109
   PubMed Web of Science ®Google Scholar
• SaiKKaniwaNItodaMHaplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecanPharmacogenetics20031374175714646693
   PubMedGoogle Scholar
• KimRBMDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequencesPharmacogenetics20021242542712172210
   PubMedGoogle Scholar
• HoskinsJMMarcuelloEAltesAIrinotecan pharmacogenetics: influence of pharmacodynamic genesClin Cancer Res2008141788179618347181
   PubMed Web of Science ®Google Scholar
• DehalSSKupferDCYP2D6 catalyzes tamoxifen 4-hydroxylation in human liverCancer Res199757340234069270005
   PubMed Web of Science ®Google Scholar
• DestaZWardBASoukhovaNVComprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6J Pharmacol Exp Ther20043101062107515159443
   PubMed Web of Science ®Google Scholar
• PartePKupferDOxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobinDrug Metab Dispos2005331446145215987777
   PubMed Web of Science ®Google Scholar
• CreweHKNotleyLMWunschRMMetabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifenDrug Metab Dispos20023086987412124303
   PubMed Web of Science ®Google Scholar
• StearnsVJohnsonMDRaeJMActive tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineJ Natl Cancer Inst2003951758176414652237
   PubMed Web of Science ®Google Scholar
• JinYDestaZStearnsVCYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentJ Natl Cancer Inst200597303915632378
   PubMed Web of Science ®Google Scholar
• LimHSJu LeeHSeok LeeKClinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancerJ Clin Oncol2007253837384517761971
   PubMed Web of Science ®Google Scholar
• HoskinsJMCareyLAMcLeodHLCYP2D6 and tamoxifen: DNA matters in breast cancerNat Rev Cancer2009957658619629072
   PubMed Web of Science ®Google Scholar
• HigginsMJStearnsVCYP2D6 polymorphisms and tamoxifen metabolism: clinical relevanceCurr Oncol Rep20101271520425602
   PubMed Web of Science ®Google Scholar
• SchrothWGoetzMPHamannUAssociation between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenJAMA20093021429143619809024
   PubMed Web of Science ®Google Scholar
• BonanniBMacisDMaisonneuvePPolymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen TrialJ Clin Oncol20062437083709 author reply370916877740
   PubMed Web of Science ®Google Scholar
• NowellSAAhnJRaeJMAssociation of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsBreast Cancer Res Treat20059124925815952058
   PubMed Web of Science ®Google Scholar
• NowellSSweeneyCWintersMAssociation between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapyJ Natl Cancer Inst2002941635164012419790
   PubMed Web of Science ®Google Scholar
• DavisWVenittSPhillipsDHThe metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphationCarcinogenesis1998198618669635875
   PubMed Web of Science ®Google Scholar
• DasaradhiLShibutaniSIdentification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifenChem Res Toxicol1997101891969049430
   PubMed Web of Science ®Google Scholar
• JinYHayesDFLiLEstrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapyJ Clin Oncol2008265849585419018086
   PubMed Web of Science ®Google Scholar
• ZhangQXBorgAWolfDMAn estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancerCancer Res199757124412499102207
   PubMed Web of Science ®Google Scholar
• SolusJFAriettaBJHarrisJRGenetic variation in eleven phase I drug metabolism genes in an ethnically diverse populationPharmacogenomics2004589593115469410
   PubMed Web of Science ®Google Scholar
• MizutaniTPM frequencies of major CYPs in Asians and CaucasiansDrug Metab Rev2003359910612959412
   PubMed Web of Science ®Google Scholar
• XieHGKimRBWoodAJMolecular basis of ethnic differences in drug disposition and responseAnnu Rev Pharmacol Toxicol20014181585011264478
   PubMed Web of Science ®Google Scholar
• Suarez-KurtzGPharmacogenomics in admixed populationsTrends Pharmacol Sci20052619620115808344
   PubMed Web of Science ®Google Scholar
• SistonenJSajantilaALaoOCYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structurePharmacogenet Genomics2007179310117301689
   PubMed Web of Science ®Google Scholar
• RoyJNLajoieJZijenahLSCYP3A5 genetic polymorphisms in different ethnic populationsDrug Metab Dispos20053388488715833928
   PubMed Web of Science ®Google Scholar
• BozinaNBradamanteVLovricMGenetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer riskArh Hig Rada Toksikol20096021724219581216
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMPharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and futureTrends Pharmacol Sci20042519320015063083
   PubMed Web of Science ®Google Scholar
• AgundezJAPolymorphisms of human N-acetyltransferases and cancer riskCurr Drug Metab2008952053118680472
   PubMed Web of Science ®Google Scholar
• HamdySIHiratsukaMNaraharaKGenotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian populationBr J Clin Pharmacol20035556056912814450
   PubMed Web of Science ®Google Scholar
• FungKLGottesmanMMA synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein functionBiochim Biophys Acta2009179486087119285158
   PubMed Web of Science ®Google Scholar
• LeslieEMLetourneauIJDeeleyRGFunctional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1)Biochemistry2003425214522412731862
   PubMed Web of Science ®Google Scholar
• ConradSKauffmannHMItoKA naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistancePharmacogenetics20021232133012042670
   PubMedGoogle Scholar
• HulotJSVillardEMaguyAA mutation in the drug transporter gene ABCC2 associated with impaired methotrexate eliminationPharmacogenet Genomics20051527728515864128
   PubMed Web of Science ®Google Scholar
• MizuaraiSAozasaNKotaniHSingle nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2Int J Cancer200410923824614750175
   PubMed Web of Science ®Google Scholar
• TamuraAWakabayashiKOnishiYRe-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2Cancer Sci20079823123917297656
   PubMed Web of Science ®Google Scholar
• TamuraAWatanabeMSaitoHFunctional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transportMol Pharmacol20067028729616608919
   PubMed Web of Science ®Google Scholar
• KonigJSeithelAGradhandUPharmacogenomics of human OATP transportersNaunyn Schmiedebergs Arch Pharmacol200637243244316525793
   PubMed Web of Science ®Google Scholar
• ZairZMElorantaJJStiegerBPharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidneyPharmacogenomics2008959762418466105
   PubMed Web of Science ®Google Scholar
• MarzoliniCTironaRGKimRBPharmacogenomics of the OATP and OAT familiesPharmacogenomics2004527328215102542
   PubMed Web of Science ®Google Scholar
• ZhouFYouGMolecular insights into the structure-function relationship of organic anion transporters OATsPharm Res200724283617103332
   PubMed Web of Science ®Google Scholar
• WaltherAJohnstoneESwantonCMidgleyRTomlinsonIKerrDGenetic prognostic and predictive markers in colorectal cancerNat Rev Cancer2009948949919536109
   PubMed Web of Science ®Google Scholar
• van ErpNPBakerSDZhaoMEffect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecanClin Cancer Res2005117800780616278402
   PubMed Web of Science ®Google Scholar